Potential role of the IL-33/ST2 axis in celiac disease

Cellular and Molecular Immunology

Volumn 14, Issue 3, 2017, Pages 285-292

  Lopez Casado M A ^a   Lorite, P ^b   Palomeque, T ^b   Torres, M I ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

celiac disease; gluten peptides; IL 33; ST2

Indexed keywords

BIOLOGICAL MARKER; GLIADIN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; IL1RL1 PROTEIN, HUMAN;

ARTICLE; BARLEY; CELIAC DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; HLA DQ2 GENE; HLA DQ8 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTESTINE BIOPSY; MALE; MOLECULAR PATHOLOGY; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SCHOOL CHILD; SEROLOGY; TISSUE DISTRIBUTION; TISSUE LEVEL; WHEAT; BIOPSY; BIOSYNTHESIS; BLOOD; GENETICS; IMMUNOHISTOCHEMISTRY; INFANT; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SOLUBILITY;

BIOPSY; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; FEMALE; HLA-DQ ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; INTESTINAL MUCOSA; MALE; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 85014588626     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.85     Document Type: Article

References (39)

1. Sollid LM. Celiac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2000; 2: 647-655
2. Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 2005; 142: 289-298
3. Torres MI, López-Casado MA, Luque J, Peña J, Ríos A. New advances in celiac disease: serum and intestinal expression of HLA-G. Int Immunol 2006; 18: 713-718
4. Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology 2005; 128: S68-S73
5. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101: 4175-4179
6. Torres MI, López Casado MA, Ríos A. New aspects in celiac disease. World J Gastroenterol 2007; 13: 1156-1161
7. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989; 169: 345-350
8. Anderson RP, Degano P, Godkin AJ. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337-342
9. Shan L, Molberg Ø, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275-2279
10. Comino I, Real A, Gil-Humanes J, Pistón F, De Lorenzo L, Moreno Mde L, et al. Significant differences in celiac immunotoxicity of barley varieties. Mol Nutr Food Res 2012; 56: 1697-1707
11. Comino I, Real A, De Lorenzo L, Cornell H, López-Casado Mê , Barro F, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in celiac disease. Gut 2011; 60: 915-922
12. Real A, Comino I, De Lorenzo L, Merchán F, Gil-Humanes J, Giménez MJ, et al. Molecular and immunological characterization of gluten proteins isolated from oat cultivars that differ in toxicity for celiac disease. PLoS One 2012; 7: e48365. doi: 10.1371/journal.pone. 0048365
13. Arend WP, Palmer G, Gabay C. IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38
14. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89-102
15. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-110
16. Murphy GE, Xu D, Liew FY, McInnes IB. Role of interleukin 33 in human immunopathology. Ann Rheum Dis 2010; 69: i43-i47
17. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatinassociated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104: 282-287
18. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490
19. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol 2009; 30: 227-233
20. Li H, Tago K, Io K, Kuroiwa K, Arai T, IwahanaH, et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics 2000; 67: 284-290
21. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42: 358-364
22. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164: 277-281
23. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Comm 2001; 284: 1104-1108
24. Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012; 79: 32-37
25. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282: 26369-26380
26. Marsh MN. Gluten, major histocompatibility complex and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102: 330-354
27. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of celiac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11: 1185-1194
28. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. InflammBowel Dis 2010; 16: 109-117
29. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007; 10: 2779-2786
30. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490
31. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells. Int Immunol 2008; 20: 1019-1030
32. Pastorelli L, De Salvo C, Vecchi M, Pizarro TT. The role of IL-33 in gut mucosal inflammation. Mediators Inflamm 2013; ID 608187: 11 p
33. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, et al. Caspase-1, caspase-8 and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009; 183: 7890-7897
34. Moulin D, DonzéO, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-225
35. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD81 T cells. Eur J Immunol 2011; 41: 3351-3360
36. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009; 39: 1046-1055
37. Lecart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002; 32: 2979-2987
38. Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012; 58: 6-9
39. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2010; 49: 520-527